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The function and the role of glucosylceramide have not been well studied in the central nervous system. This study was aimed
to investigate the possible roles of glucosylceramide in memory function in aged mice. Glucosylceramide (50mg/kg, p.o.) showed
memoryenhancingactivityafter3-monthtreatmentintheagedmice(C56BL/6,18–20monthsold)throughY-maze,novelobjective
test, and Morris water maze test. Long-term treatment of glucosylceramide decreased the expression of iNOS and COX-2 in the
brain of aged mice. The LPS-induced mRNA level of iNOS, COX-2, IL-1𝗽,a n dT N F - 𝗼 was reduced by the acute treatment with
glucosylceramide in adult mice. These results suggest that glucosylceramide plays an important role in anti-inflammatory and
memory enhancement, and it could be a potential new therapeutic agent for the treatment of neurodegenerative diseases such as
Alzheimer’s disease.
1. Introduction
Age-relateddeteriorationofbrainfunctionproducesavariety
of behavioral deficits. Age-related impairments in cognitive
function include memory and spatial ability [1]. During
normal aging the brain undergoes many changes resulting in
a detectable cognitive decline that is associated with limited
neuronal loss, glial proliferation in the cortex [2, 3]. On the
molecular level, the mechanisms about aging of the brain
are not yet understood. But aging is a biological process
characterized by time-dependent functional declines that
are influenced by changes in inflammatory reactions. An
organism’s proinflammatory status may underlie the aging
process and age-related diseases. Chronic inflammation in
aging is related to age-associated disorders (e.g., Alzheimer
disease, etc.). The pathophysiological events involved in
the neuronal dysfunction and degeneration in aging are
considered to be the increased inflammation [4]. Neuroin-
flammation, which develops with age, is closely related to
neuronal degeneration and cognitive impairment [5]. The
neuroinflammation includes that microglial and astrocytic
responsesreleasereactiveoxygenspecies(ROS),nitricoxide,
excitatory amino acids, and cytokines, which may result in
neurodegeneration[5,6].Alinkbetweensystemicinflamma-
tion and dementia was first hypothesized after discovery of
upregulated inflammatory processes localized to Alzheimer’s
disease (AD) pathology in postmortem brain specimens [7].
In cross-sectional analysis of clinical populations, a rea-
sonably consistent finding has been an association between
dementia and higher levels of IL-1𝗽, IL-6, C-reactive protein,
andTNF-𝗼[8].Thereforecertaincompoundthathastheanti-
inflammatory properties can be a good candidate for healthy
aging therapy [9]. The aged mice models have been used to
screen for potential treatments for cognitive dysfunction.
In regard to brain functions, the major findings have
emphasized the significance of sphingolipids as bioactive
molecules that control diverse cellular processes such as pro-
liferation, differentiation, growth, migration, and apoptosis
[10]. Sphingolipid metabolites especially, such as ceramide
a n ds p h i n g o s i n e1 - p h o s p h a t e( S 1 P ) ,h a v er e c e i v e dm u c h
attention as key regulators of cell death and survival [11]. In
sphingolipidpathway,sphingosineisphosphorylatedtoform2 Evidence-Based Complementary and Alternative Medicine
S1P by sphingosine kinases. Because the phosphorylation
of sphingosine is the only pathway for the formation of
S1P, cellular S1P is highly dependent on the availability of
sphingosine generated by ceramidases. Ceramide mediates
a wide array of the stress signals leading to growth arrest
or cell death, whereas S1P exerts prosurvival capabilities by
antagonizing ceramide effects [12]. The major sphingoid base
of mammalian cells is sphingosine and dihydrosphingosine.
Our previous studies showed that phytoceramide ame-
liorated the scopolamine-induced memory impairment and
showed neuroprotection [13]. Structurally, sphingosine is
primary amine containing primary and secondary alcohol
g r o u p sw h i l ec e r a m i d eh a sa m i d eg r o u pw i t ha l c o h o l s .
Ceramideisatthecenterofsphingolipidmetabolismandhas
been recognized as a critical second messenger. In addition,
glucosylceramide is composed of glucose group at primary
alcohol position on the ceramide backbone (Figure 1), and
glucosylceramide is a major sphingolipid in plants such
as soybean, corn, rice, and wheat [14]. Glucosylceramide
has recently attracted interest since the beneficial effects of
glucosylceramide in improving the skin barrier function by
dietary administration as well as topical application [15, 16].
Recently,itisaninterestingreportthatoraladministrationof
glucosylceramide strongly suppressed mRNA expression of
the proinflammatory cytokines IL-1𝗽 a n dI L - 6i nm i c e[ 17].
A direct linkage to the sphingolipid metabolism with the
neuronal function has not been established well, and it is
not understood how such lipid metabolites lead to neuronal
dysfunction or survival. Therefore, the current study focused
on the effects of the glucosylceramide on the neuronal func-
tions and made a search for the evidence on the relationship
between the glucosylceramide and neuronal functions in
memory impairment after oral administration. To achieve
the objective of the study, the memory performance was
examined by using several behavioral tasks in aged mice
w h i c hw e r ei m p a i r e di nm e m o ry .
2. Materials and Methods
2.1. Animals and Drug Treatment. The male C57BL/6 mice
(28–30g) were purchased from the Orient Lab Animal
(Seoul,RepublicofKorea).Miceallowingaccesstowaterand
food ad libitum were grouped 5-6 per cage and maintained
at an ambient temperature of 23
∘Ca n da1 2hd i u r n a ll i g h t
cycle (light on 07:00–19:00). Mice were raised and housed at
the laboratory in transparent polycarbonate cages until 18–
20 months old. Mice were given experimental diet pellets
whichcontainsglucosylceramidefor3months.Allbehavioral
experiments were carried out in a room adjacent to that in
which the mice were housed under the same conditions of
temperatureandlightcycle.Alltheexperimentswerecarried
out using male C57BL/6 mice according to the guidelines of
the Animal Care and Use Guidelines of School of Medicine,
Ewha Womans University, Republic of Korea.
2.2. Glucosylceramide. The plant ceramide (gluco-sylceram
ide) from soybean origin was kindly provided by Doosan
Co., Glonet Biotech Division (Suwon, Republic of Korea)
[17]. The applied glucosylceramide formula contains 61.3%
glucosylceramide, 11.5% steryl glycoside, 7.4% phosphatidyl-
choline, 6.2% phosphatidylinositol, 3.5% triglyceride, 3.5%
lysophosphatidylcholine, 2.4% free fatty acid, and so forth.
The glucosylceramide was comprised primarily of ceramide
with4,8-sphinganine(d18:2)andalpha-hydroxypalmiticacid
(h16:0).
Glucosylceramide was readily characterized through
physicochemical instruments after purification by flash col-
umn chromatography. Flash column chromatography was
p e r f o r m e dw i t hM e r c ks i l i c ag e l6 0( 2 3 0 – 4 0 0 m e s h )f o r
purification.
1HN M Ra n d
13C NMR spectra were recorded
on Bruker DPX 400 at 400MHz and 100MHz, respectively.
Protonchemicalshiftsarereportedinppmrelativetointernal
tetramethylsilane(TMS)orwiththesolventreferencerelative
to TMS employed as the internal standard (CDCl3). Data
are reported as follows: chemical shift {multiplicity [singlet
(s), doublet (d), triplet (t), quartet (q), and multiplet (m)],
couplingconstants[Hz],integration}.Carbonchemicalshifts
a r er e p o r t e di np p mr e l a t i v et oT M Sw i t ht h er e s p e c t i v e
solvent resonance as the internal standard (CDCl3). Infrared
(IR)spectrawererecordedonaJASCOFT/IR-430spectrom-
eter. Data are reported in wave numbers (cm
−1). Melting
Points were determined on a BIBBY Stuart Scientific Melting
Point Apprataus SMP3. Mass spectra were recorded with a
Waters Micromass ZQ LC-Mass system and high resolution
mass spectra (HRMS) were measured with a Bruker BioApex
FTMS system by direct injection using an electrospray inter-
face (ESI).
Glucosylceramide: mp: 195-196
∘C; IR (neat, NaCl) 3353
(O–H), 2920 (C–H), 2851, 1726 (C=O), 1620 (C=C), 1530,
1466, 1406, 1378, 1264, 1182, 1168, 1040 (C–O), 721cm
−1;
1H
N M R( 4 0 0M H z ,C D C l 3) 𝗿 5.60–5.52 (m, 2H), 5.42–5.28 (m,
2H), 5.01–4.87 (m, 1H), 4.55–4.48 (m, 1H), 4.13–4.09 (m,
1H), 4.04–3.99 (m, 1H), 3.85–3.78 (m, 2H), 3.54–3.28 (m,
6H), 2.50 (brs, 6H), 2.05–1.90 (m, 6H), 1.54–1.45 (m, 2H),
1.33–1.19 (m, 38H), 0.88–0.81 (m, 6H);
13C NMR (100MHz,
CDCl3) 𝗿 173.75, 132.31, 130.23, 129.73, 127.76, 76.89, 76.53,
73.11, 71.59, 70.01, 33.91, 33.22, 32.54, 31.99, 31.29, 30.89, 29.03,
28.71, 28.58, 26.59, 25.21, 24.43, 22.09, 21.96, 14.11; HRMS
calcd. for C40H76NO9: 714.5520 [M+H]
+, found: 714.5531.
2.3. Behavioral Test for Learning and Memory
2.3.1. Y-Maze Test. Spontaneous spatial recognition in the Y-
mazewasusedasahippocampus-dependenttest.TheY-maze
is a three-arm horizontal maze (40cm long and 3cm wide
with 12cm high walls) in which the arms were symmetrically
disposed at 120
∘ angles from each other. The maze floor and
walls were constructed from dark opaque polyvinyl plastic.
Mice were initially placed within one arm, and the sequence
(i.e., ABCAB, etc.) and number of arm entries were recorded
manually for each mouse over 8-minute period. An actual
alternation was defined as entries into all three arms on
consecutive choices (i.e., ABC, CAB, or BCA but not BAB).
Mazearmswerethoroughlycleanedbetweentaskstoremove
residual odors. One hour after the last administration of
glucosylceramide or saline alone, memory impairment wasEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Structures of sphingosine, phytoceramide, and glucosylceramide.
tested.Miceweregentlyplacedinthemaze.Thepercentageof
alternationswasdefinedaccordingtothefollowingequation:
%alternation=[(numberofalternations)/(totalarmentries−
2)] × 100. The number of arm entries served as an indicator
of locomotor activity.
2.3.2.NovelObjectRecognition. Thistestwasusedtomeasure
for objective recognition. The arena was a cage bottom (30 ×
40 × 20cm) with black walls. The objects were the same size
b u td i ff e r i n gi ns h a p e ,c o l o r ,a n ds u r f a c et e x t u r e .O nd a y1 ,
each mouse was habituated individually to the test box for
8min sessions in which the animals were allowed to freely
explore the open field box. After 6h, two identical objects
were placed in each corner and the mouse was allowed 8min
to explore the objects. Pairs of each object were used for an
e q u a ln u m b e ro ft i m e s .O nd a y2o n eo b j e c tw a sr e p l a c e d
withanovelobjectinacounter-balancedfashionwithrespect
to object, side, and genotype. The mouse was allowed 8min
to explore the familiar and novel object while it was video-
recorded. Exploration was defined as sniffing the object or
having one or both forepaws touching the object. From the
absolute exploration duration (𝑇) an exploration index was
calculated:[(𝑇Novel−𝑇 Familiar)/(𝑇Novel+𝑇 Familiar)]×100. This
measureisconsideredasanindexofrecognitionmemoryand
takes into account individual differences in the total amount
of object exploration time.
2.3.3. Morris Water Maze Test. Young and aged mice were
tested in a standardized assessment of spatial cognition prior
to behavioral studies with Morris water maze protocol as
described in detail elsewhere [18]. The Morris water maze
is a circular pool (90cm in diameter and 45cm in height)
with a featureless inner surface. The pool was filled to a
depthof30cmwithwatercontaining3000mLofmilk(20
∘C).
The tank was placed in a dimly lit, soundproof test room
with various visual cues. The pool was conceptually divided
into quadrants. A white platform (6cm in diameter and
29cm high) was then placed in one of the pool quadrants
and submerged 1cm below the water surface so that it
was invisible at water level. The first experimental day was
dedicated to swimming training for 60sec in the absence of
the platform. During the four subsequent days the mice were
given four trials per day with the platform in place. When
a mouse located the platform, it was permitted to remain
on it for 10sec. If the mouse did not locate the platform
within 60sec, it was placed on the platform for 10sec. The
animal was taken to its home cage and was allowed to dry
up under an infrared lamp after each trial. The time interval
between each trial was 30sec. During each trial, the time
taken to find the hidden platform (latency) was recorded
using a video camera-based Ethovision System (Nodulus,
Wageningen, The Netherlands). For each training trial, mice
wereplacedinthewaterfacingthepoolwallatoneofthepool
quadrants in a different order each day. One day after the last4 Evidence-Based Complementary and Alternative Medicine
training trial sessions, mice were subjected to a probe trial
s e s s i o ni nw h i c ht h ep l a t f o r mw a sr e m o v e df r o mt h ep o o l ,
allowing the mice to swim for 60sec to search for it. A record
was kept of the swimming time in the pool quadrant where
the platform had previously been placed. Glucosylceramide
(50mg/kg, p.o.) was given 1h before the first trial session at
every consecutive day. Control group received saline only.
2.4.ImmunoblotAnalysis. Thebraintissuewashomogenized
with homogenization buffer (0.25M sucrose, 10mM Tris-cl
p H 7 . 4 ,0 . 5m ME D T A ,1m MP M S F ,a n d1m MN a 3VO4) and
centrifuged at 13500rpm for 15min twice at 4
∘C. Samples
were assayed for protein concentration using protein assay
kit (Pierce Chemical, Rockford, IL, USA). Proteins were sep-
arated by SDS-polyacrylamide gel electrophoresis and trans-
ferred to a polyvinylidene difluoride membrane. The mem-
brane was blocked with 5% nonfat dry milk in Tris-buffered
saline/Tween 20 solution. The blots were incubated with
the iNOS and COX-2 (Millipore Technology Inc., Danvers,
MA, USA). GAPDH (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA) was performed as an internal control. After
washing with Tris-buffered saline/Tween 20, horseradish
peroxidase-conjugated secondary antibodies (Cell Signaling
Technology Inc.) were applied, and the blots were developed
using the enhanced chemiluminescence detection kit (GE
Healthcare, Chalfont St. Giles, Buckinghamshire, UK).
2.5. Polymerase Chain Reaction. Mice were stimulated with
L P Si nt h ea b s e n c eo rp r e s e n c eo fg l u c o c e r a m i d ef o r1 8 h .
Total RNA was isolated from hippocampus of mice using
TRIzol (Invitrogen) according to the manufacturer’s instruc-
tions. For cDNA synthesis, 2ug of total RNA was reverse-
transcribedusing the SuperScriptFirst-StrandSynthesisSys-
tem (Invitrogen). cDNA was amplified by polymerase chain
reaction (PCR) using primers for iNOS (F:GTGTTCCAC-
CAGGAGATGTTG,R:CTCCTGCCCACTGAGTTCGTC-
),COX-2(F:AAGACTTGCCAGGCTGAACT,R:CTTCTG-
CAGTCCAGGTTCAA),IL-1𝗽(F:AGCAACGACAAAA-
TACCTGT,R:CAGTCCAGCCCATACTTTAG)andTNF-
𝗼(F:TGTCTCAGCCTCTTCTCATT,R:GTATGAGATAG-
CAAATCGGC);PCRproductswereseparatedby1%agarose
gel electrophoresis and visualized by ethidium bromide
staining.
2.6. Statistical Analysis. All values were expressed as mean ±
standard error (SE). The results were subjected to an analysis
of the variance (one-way ANOVA) using the Newman-Keuls
multiple comparison test. Differences with
∗𝑃 < 0.05 were
consideredasstatisticallysignificanttoanalyzethedifference.
3. Results
3.1. Amelioration of the Memory Deficits in Aged Mice through
Y-Maze Test. To determine whether glucosylceramide mod-
ulate the memory function, aged mice (C57BL/6 male,
18–20 months old) were tested in the Y-maze test. Mice
were administrated for 3 months with glucosylceramide
(50mg/kg) which mixed in the chow. Aged mice showed
the impairment in working memory function since aged
mice spent less spontaneous alteration than young mice in
Y-maze test. Glucosylceramide enhanced spatial memory
since glucosylceramide-treated mice spent higher sponta-
neous alteration in the novel arm than that of saline group
[𝐹(2,21) = 8.388, 𝑃 = 0.0021, one-way ANOVA]. Glucosyl-
ceramide resists the working memory retention. There was
significant effect on the percentage of alternation (Figure 2).
3.2.AmeliorationoftheMemoryDeficitsinAgedMicethrough
Novel Object Task. The amount of time spent with the
n o v e lo b j e c tc o m p a r e dw i t ht h et o t a lt i m es p e n te x p l o r -
ing both object represents an index of long-term mem-
ory. Mice were administrated with glucosylceramide for 3
months(50mg/kg).Treatmentofglucosylceramideenhances
memory function on the performance of a novel object
recognition task (Figure 3). As expected, in the training
session (Figure 3(a)) ,t h ea g e dm i c eg r o u p ss p e n ts i m i l a r
times investigating each of the identical objects and there
were no differences in total exploration times between the
test groups. During training, animals showed no preference
for one object over another and there was no difference
between aged mice in the exploration time, suggesting that
the experimental groups were on average equally motivated
to explore objects (Figure 3(b)). However, when presented
with a novel object, glucosylceramide-treated mice showed a
preference for the new one after 24h of retention [𝐹(2,21) =
11.41,𝑃 = 0.004, one-way ANOVA].
3.3. AmeliorationoftheMemoryDeficitsinAgedMicethrough
Morris Water Maze Test. The effects of glucosylceramide
on learning and spatial memory were evaluated by the
Morris water maze test. Mice were administrated with glu-
cosylceramide (50mg/kg) for 3 months. The aged group
exhibited longer escape latencies throughout the training
days than that of the young group. Glucosylceramide group
significantly shortened the escape latencies which was pro-
longed by aged group (𝑃 < 0.05). On the day following
the final day of training trial sessions, swimming times
withintheplatformquadrantfortheglucosylceramidegroup
were significantly lower than those of the vehicle-treated
young group (𝑃 < 0.05)( Figure 4). Moreover, the short-
ened swimming time within the platform quadrant in aged
group was significantly increased in glucosylceramide group
[𝐹(2,21) = 17.69,𝑃 = 0.0001, one-way ANOVA]. However,
nosignificantdifferencesinswimmingspeedswereobserved
between the groups. In this experiment, aged mice increased
the escape latency time at the training sessions; however,
glucosylceramide treatment shortened this escape latency
time on day 4. At the probe trial session, glucosylceramide
treatment increased the swimming time within the target
q u a d r a n t .Th ed e c r e a s ei ne s c a p el a t e n c yf r o md a yt od a y
in the first trial represents long-term memory or reference
memory, while that from first trial of sessions to second
trial of sessions represents short-term memory or working
memory [19]. The time in the quadrant with the platform
reflectschangesinspatialmemory[20]. These results suggestEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Effects of glucosylceramide on the memory deficit aged mice through Y-maze test. One hour after the administration of
glucosylceramide(50mg/kg)orsalinealone,memoryimpairmentwastested.Miceweregentlyplacedinthemaze.Micewereinitiallyplaced
within one arm, and the sequence (i.e., ABCAB, etc.) and number of arm entries were recorded manually for each mouse over 8-minute
period. The percentage of alternations was defined according to the following equation: %alternation = [(number of alternations)/(total arm
entries − 2)] × 100. The number of arm entries served as an indicator of locomotor activity. Results are expressed as means ± S.E.M. 𝑛=8in
each group.
#𝑃 < 0.05 in comparison with young,
∗𝑃 < 0.05 in comparison with saline group (𝑛=8mice in each group).
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Figure 3: Performance of a novel object recognition task in young and aged mice. (a) The training [(𝑇Novel −𝑇 Familiar)/(𝑇Novel +𝑇 Familiar)] ×
100 session; (b) the test session conducted 24h after the training session. During the testing session of the novel object recognition memory
task, mice treated with saline or glucosylceramide. Mice were administrated with the glucosylceramide (50mg/kg) for 3 months. Results are
expressed as means ± S.E.M. (𝑛=8in each group).
that glucosylceramide improves the long-term memory in
amnesic aged mice.
3.4. Decreasing the iNOS and COX-2 Protein Expression by
Long-Term Glucosylceramide Administration in Aged Mice.
Glucosylceramide exerted an anti-inflammatory effect on
age-related responses accompanied by the expression of
i N O Sa n dC O X - 2 .A g e dm i c ew e r ea d m i n i s t r a t e dw i t h
glucosylceramide for 3 months. The protein expression levels
o ft h ei N O Sa n dC O X - 2i nh i p p o c a m p u so fb r a i nw e r e
reduced by administration of glucosylceramide (Figure 5).
These results indicated that glucosylceramide had an anti-
inflammatory effect on the expression of age-related proin-
flammatory signals in aged mice.
3.5. Decreasing the iNOS, COX-2, and Proinflammatory
Cytokines mRNA Expression by Glucosylceramide Treatment6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Effect of glucosylceramide on the memory deficit in aged mice through Morris water maze task. Glucosylceramide (50mg/kg) or
vehicle (saline) was orally administered to mice for 3 months before training trial session. The training trial and the probe trial sessions were
performed as described in Section 2. Results are expressed as means ± S.E.M.
#𝑃 < 0.05 in comparison with young group,
∗𝑃 < 0.05 in
comparison with saline group (𝑛=8in each group).
in LPS-Induced Mice. Glucosylceramide exerted an anti-
inflammatory effect on LPS-induced responses accompanied
by the expression of proinflammatory cytokines in adult
mice.Hippocampusofmicewascollected18haftertreatment
of glucoceramide and LPS. The mRNA expression levels
of the iNOS, COX-2, IL-1𝗽,a n dT N F - 𝗼 were reduced by
treatment with glucosylceramide (Figure 6). These results
indicated that glucosylceramide has an anti-inflammatory
effect on the expression of LPS-induced proinflammatory
cytokines in the brain of mice.
4. Discussion
Aging is an important risk factor for Alzheimer’s disease
(AD) [21, 22]. But the factors that cause the relatively benign
process of normal brain aging to the pathological cascade
that leads to AD are unknown. Age-related deterioration of
brain function produces a variety of behavioral deficits like
age-related impairments in cognitive functions, including
memory and spatial ability. Recently, neuroinflammatory
processes have been identified as key early events strongly
implicated in cognitive dysfunction linked to age [23]. The
inflammatory cytokine was initially found to be increased in
blood of healthy aged humans [24]a n dm i c e[ 25]. Support
of this theory comes from studies reporting a progressive,
age-associated increase in activated microglia. Alterations in
microglial function have been linked to the development of
neurodegenerative diseases [26]. Aging changes have been
hypothesized to drive the pathogenic progression through
a diminution of neuroprotective functions, direct increases
in neurotoxicity, and dysregulated responses to signals [27–
29]. Age-related alterations previously are characterized in
somechangesinmicrogliaincludingchangesincytokinepro-
duction [30–34], increased expression of activation markers
[35–38]. This is in accordance with results obtained in ourEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: Effect of glucosylceramide on the inflammation-related signals in the hippocampus of mice. Mice were administered with
glucosylceramide (50mg/kg) for 3 months. The expression of iNOS and COX-2 in hippocampus of brain was measured by immunoblot
analysis. Glucosylceramide treatment decreased the expression of iNOS and COX-2 in aged mice. GAPDH was used as an internal control.
All values are expressed as mean ± S.E.M. from two independent experiments (𝑛=4 ).
∗𝑃 < 0.05 indicates significant difference between the
aged group and glucosylceramide-treated group.
iNOS
COX-2
IL-1𝗽
TNF-𝗼
𝗽-actin
Vehicle Sal GC25 GC50
LPS
(a)
E
x
p
r
e
s
s
i
o
n
 
d
e
n
s
i
t
y
 
(
%
)
0
20
40
60
80
100
∗ ∗
iNOS COX-2 IL-1𝗽 TNF-𝗼
Sham
LPS
LPS + GC25
LPS + GC50
∗
∗
∗
∗
∗
(b)
Figure 6: Effect of glucosylceramide on pro-inflammation-related signals in hippocampus of mice. Adult mice were treated with 1mg/kg
LPS (i.p.) to induce inflammation and glucosylceramide (GC 25, 50mg/kg, p.o.) was pretreated 1hr before LPS injection. The expression of
mRNA of iNOS, COX-2, IL-1𝗽,a n dT N F - 𝗼 was measured at 18h after LPS injection by immunoblot analysis. 𝗽- a c t i nw a su s e da sa ni n t e r n a l
control. All values are expressed as mean ± S.E.M. from two independent experiments (𝑛=4 ).
∗𝑃 < 0.05 indicates significant difference
between the LPS group and glucosylceramide-treated group in aged mice.
experiment (unpublished data) and others by showing that
inflammatory events induce production of proinflammatory
cytokines in the hippocampus, followed by impairments in
spatial memory and learning [39].
In the present study, it was shown that long-term
administrationofglucosylceramideamelioratedthememory
decline and anti-inflammatory activity in aged mice. The
memoryenhancingeffectofglucosylceramidewasconfirmed
in the Y-maze test, novel objective test, and Morris water
maze task in different behavioral observation. In the Morris
water maze test, glucosylceramide increased the swimming
time within the target quadrant. The decrease in escape
latency from day to day in the first trial represents long-term
memory or reference memory [19]. The time in the quadrant
with the platform reflects changes in spatial memory [40].
These results suggest that glucosylceramide improves the
long-term memory in amnesic mouse models induced by
ageing.8 Evidence-Based Complementary and Alternative Medicine
Mice fed with the control diet displayed decreasing
spatial memory performances with age. This was confirmed
to increase markers of inflammation such as iNOS and
C O X - 2a sw e l la sm R N Al e v e l si nt h eh i p p o c a m p u sa n d
inhibit hippocampal-dependent working memory. However,
administration of glucosylceramide decreased the age-
associated expression of proinflammatory mediators such as
iNOS and COX-2 in the aged mice brain and performance
in the hippocampal-dependent working memory task was
restored. Thus, age-related conditions that are exacerbated
by inflammation, including cognitive aging and neurode-
generative diseases, may be inhibited by dietary intake of
glucosylceramide. Also pretreatment of glucosylceramide
suppressed the LPS-induced proinflammatory responses;
iNOS, COX-2, and cytokines in mice.
Ceramide has been known as a sphingolipid with
potentproinflammatoryandproapoptoticproperties[41–43]
and its active metabolite, ceramide 1-phosphate, stimulates
macrophage proliferation through activation of the PI3-
k i n a se ,J N K ,a n dE R Kp a t h w a y s[ 44]. However, studies using
primary cultures of neurons demonstrated that ceramide
has multiple functions, depending on the cell type and the
developmental stage. In immature hippocampal neurons,
ceramide plays bipotential roles in cell survival and dendrite
outgrowth in a dose-dependent manner [45]. It was also
found that ceramide prevents cell death of motoneurons
cultures through inhibition of oxidative signals [46]. These
results suggest that the cellular level of ceramide is critical
for regulation of neuronal survival and differentiation. In
ourpreviousstudies,phytoceramideinhibitedtheglutamate-
induced neurotoxicity in cultured neuronal cells, while phy-
tosphingosine did not show the neuroprotective effect with
t h es a m ed o s eo fp h y t o c e r a m i d ei nt h ec u l t u r e dn e u r o n a l
cells [13]. There are some structural differences between
phytoceramide and phytosphingosine. Phytosphingosine is
structurally similar to sphingosine, except that phytosphin-
gosine has a hydroxyl group at C-4 of the sphingoid long-
chainbaseinsteado fthetrans-doublebondbetweenC-4and
C-5. There is an interesting report that phytoceramide acti-
vates peroxisome proliferator-activated receptors (PPARs),
whereas ceramide and dihydroceramide do not change the
PPAR activity [47].
The structural feature of glucosylceramide is represented
a sa t t a c h e dg l u c o s eo nt e r m i n a lh y d r o x y lg r o u pw h i l et h e
normal ceramide consists of sphingoid base linked to a
fatty acid with an amide bond. In this point the glucosyl-
ceramide would be hydrolyzed by glycosidases in vivo to
generate ceramide. Even though general ceramide is formed
as potential component in biosynthesis of many complex
sphingolipids, the biological activities of ceramide showed
relatively variable activity depending on the cell types. Glu-
cosylceramidehadbettersolubilitythanthatofceramideand
showed better bioavailability. Interestingly, phytoceramide
and glucosylceramide (after hydrolysis) have three –OH
g r o u p sb u tc e r a m i d eh a st w oh y d r o x y lg r o u p s .
Collectively, glucosylceramide plays an important role in
anti-inflammatory and memory enhancement, and it could
be a potential new therapeutic agent for the treatment of
dementia.
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